Decitabine Followed by Partially Matched Related Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.
This study is a Phase II study of decitabine followed by myeloablative conditioning,
transplantation of partially HLA-mismatched bone marrow and post-transplantation
cyclophosphamide in patients with acute myelogenous leukemia, and high-risk myelodysplastic
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary objective is to determine overall survival at 100 days after transplantation following decitabine and a HLA-haploidentical bone marrow transplantation using a myeloablative preparative regimen and post-transplantation cyclophosphamide.
Mark B Juckett, M.D.
University of Wisconsin, Madison
United States: Institutional Review Board
|University of Wisconsin Hospital and Clinics||Madison, Wisconsin 53792-0001|